According to the Future Market Insights’ analysis, the injectable drugs market is set to grow at a 5.8% CAGR over the assessment period. As per the report, the market is projected to be valued at US$ 937.0 Bn by the end of 2032.
Injectable Drugs Market to Grow at 5.85 through 2032 Amid Increasing Utilization of Intravenous Drug Delivery
Cancer, cardiovascular diseases, and metabolic diseases like diabetes, are the main cause of mortality and disability in present times. Even with the understanding of scientific disease indications, it is crucial to elevate diagnosis and control the symptoms and signs of illness.
Advancements in technologies that involve optimization of the devices used for clinical conditions, be it chronic or acute, clinical innovations, bringing in minimally invasive treatments, and evolvement in clinical diagnostics and management in treating high-risk patients, are the key developments within the general healthcare industry.
Demand for related treatments is increasing, as people are now more aware of the right treatment options, doctor-guided plans, and precautionary measures to consider for serious clinical conditions.
Key players in the injectable drugs market are actively seeking to gain approvals from regulatory bodies, and develop products across the continuum of care in severe case recovery. Furthermore, the FDA is expected to approve new devices related to advanced injectable drugs and their administration, over the coming years.
“Increasing incidence of infectious diseases, oncological diseases, cardiac disorders and device innovation are prompting healthcare providers to incorporate new treatment regimens for improved patient outcome,” says an FMI analyst.
Request a Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-15073
Key Takeaways:
- By product, monoclonal antibodies held the largest share of 20.5% in the global market in 2021.
- Based on application, infectious diseases segment held the largest share of 26.4% in the global market in 2021, with the segment expected to expand at 5.7% CAGR over the forecast period.
- In terms of molecule, large molecule segment held the largest share of 51.8% in the global market in 2021.
- By route of administration, sales in the intravenous (IV) segment are expected to increase at a 5.3% CAGR over the assessment period.
- Based on distribution channel, the hospital pharmacies segment was valued at US$ 231.0 Bn in 2021.
- North America held the largest share of 31.5% in the global injectable drugs treatment market in 2021, owing to the growing government investments in healthcare and R&D activities.
Competitive Landscape
Product launches and collaborations with suppliers that have a strong position and are popular in the market are some of the key strategies of the market players operating in the global injectable drugs market. For instance:
- Merck and Gilead Sciences, Inc. (Gilead) signed an agreement in March 2021 to collaborate on the development and commercialization of long-acting HIV treatments that combine Merck’s investigational nucleoside reverse transcriptase translocation inhibitor islatravir and Gilead’s investigational capsid inhibitor lenacapavir.
- In March 2022, Sanofi IGM Biosciences, Inc. today announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites.
- In February 2022, Novartis India Limited extends access to its medicines in India by signing exclusive sales and distribution agreement with Dr. Reddy’s Laboratories
Key Segments:
By Product:
- Monoclonal Antibodies
- Immunoglobulin
- Cytokines
- Insulin
- Peptide Hormones
- Blood Factors
- Peptide Antibiotics
- Vaccines
- Small Molecule Antibiotics
- Chemotherapy Agents
- Others
By Application:
- Oncology
- Infectious Diseases
- Diabetes
- Blood disorders
- Hormonal Disorders
- Musculoskeletal Disorders
- CNS Diseases
- Pain Management
- Cardiovascular Diseases
By Molecule Type:
- Small Molecules
- Large Molecules
By Route of Administration:
- Intravenous (IV)
- Intramuscular (IM)
- Subcutaneous (SC)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East and Africa (MEA)
Ask an Analyst:
https://www.futuremarketinsights.com/ask-question/rep-gb-15073
Table of Content
- Global Injectable Drugs Market – Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supple Side Trends
1.4. Analysis and Recommendations
- Market Overview
2.1. Market Definition and Introduction
2.2. Market Taxonomy/ Research Scope
2.3. Inclusions & Exclusions
- Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
- Key Success Factors
4.1. Disease Epidemiology
4.2. Pipeline Analysis
4.3. Regulatory Scenario
4.4. Promotional Strategies, By Key Manufacturers
4.5. Supply chain Analysis
4.6. PESTEL Analysis
4.7. PORTER Analysis
4.8. Number of Clinical Trial
4.9. List of Manufacturers
TOC Continued…!
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com